Semaglutide
Metabolic
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist with 94% sequence homology to native human GLP-1. It features a C18 fatty diacid chain attached via a linker to lysine at position 26, enabling albumin binding and extended half-life of approximately 7 days in research models. Originally developed as an analog of GLP-1(7-37), Semaglutide has been extensively studied for its role in glucose-dependent insulin secretion support, glucagon suppression, gastric emptying regulation, and hypothalamic appetite signaling in metabolic and neuroendocrine research models.
$75.00
In StockFor research purposes only. Not for human consumption.
Mechanism of Action
Semaglutide binds to and activates the GLP-1 receptor (GLP1R), a class B G-protein coupled receptor expressed in pancreatic beta cells, hypothalamic nuclei, and peripheral tissues. Receptor activation stimulates adenylate cyclase via Gαs, increasing cAMP and activating PKA/EPAC pathways to support glucose-dependent insulin secretion. In hypothalamic research models, GLP1R activation in the arcuate and ventromedial nuclei modulates POMC/AgRP neuron activity, influencing energy homeostasis signaling. Semaglutide's albumin binding via the C18 fatty diacid chain confers resistance to DPP-4 degradation and extended pharmacokinetics.
Research Focus Areas
- GLP-1 receptor activation and insulin secretion research
- Hypothalamic appetite and energy homeostasis studies
- Metabolic regulation and glucose homeostasis research models
- Glucagon suppression pathway studies